About Us
Making a difference, patient by patient
US WorldMeds is a specialty pharmaceutical company that develops, licenses, and brings to market unique healthcare products designed to improve the lives of patients with challenging conditions and unmet medical needs.
Patients are key to everything that we do at US WorldMeds
Vision
We will remain a sustainable, privately held specialty pharmaceutical company.
Mission
We will develop, license, and market meaningful and accessible healthcare products that improve lives and result in a thriving community of patients, employees, and shareholders.
Values
|
Corporate Giving
US WorldMeds is committed to improving the lives of patients with challenging conditions and unmet medical needs. In alignment with this mission and the company’s Generosity of Spirit core value, USWM makes available philanthropic funding opportunities for qualified not-for-profit organizations that further the study, treatment, awareness, or patient outcomes of diseases in our areas of focus.
USWM ensures corporate giving is conducted in compliance with industry codes, relevant laws and regulations, and USWM’s policies and procedures. A recipient’s use, purchase, or prescription of USWM products or a recipient’s ability to influence the use, purchase, or prescription of USWM products will not be considered when deciding charitable giving. Eligible applicants will be tax-exempt organizations under Section 501(c)-(3) or 501(c)-(6) of the U.S. Internal Revenue Code.
USWM does not offer funding for government agencies, political purposes, religious purposes, or for any other purpose that would pose a conflict of interest or contradict USWM’s mission.
Requests for unsolicited charitable contributions will be received at corpgiving@usworldmeds.com.
If you have questions about financial support for Iwilfin™ (eflornithine) please visit IWILFIN Cares.
QUICK ACCESS TO THE LATEST COMPANY NEWS
Discover the latest news, featured stories, and past news from US WorldMeds
December 14, 2023US WorldMeds Announces FDA Approval of IWILFIN™ (eflornithine) to Strengthen Fight Against Aggressive Childhood CancerFirst and only FDA-approved oral maintenance therapy for high-risk neuroblastomaLOUISVILLE, Ky. December 14, 2023 -- USWM, LLC (US WorldMeds) today announced that the U.S. Food and Drug Administration (FDA) has approved IWILFIN™ (eflornithine) 192 mg tablets, a groundbreaking oral maintenance therapy for high-risk neuroblastoma. IWILFIN is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who have demonstrated at least a partial response to prior multiagent, multimodality therapy, including anti-GD2 immunotherapy. Read more |